Adults With Chronic Sialorrhea | XEOMIN®

Adults With Chronic Sialorrhea

XEOMIN Is the First and Only FDA–Approved Botulinum Toxin Type A for Adults With Chronic Sialorrhea, Which Impacts an Estimated 600,000 Adults in the United States1–7

  • Sialorrhea (drooling or excessive salivation) is a common problem in the neurologically impaired (i.e., those with mental retardation or cerebral palsy) and in those who have Parkinson’s disease or have had a stroke2
    • It is most commonly caused by poor oral and facial muscle control
Colin, adult patient with chronic sialorrhea treated with XEOMIN®

Colin, an adult with chronic sialorrhea treated with XEOMIN

Complications That Develop as a Result of Chronic Sialorrhea

Sialorrhea Symptoms Pinch to zoom


  • Excessive wetness
  • Skin breakdown around the mouth
  • Infection from skin breakdown
  • Dehydration or not enough fluids
  • Foul odor

Impact on Daily Living4

  • Risk of breathing problems or clogged airway
  • Swallowing or feeding difficulties
  • Greater risk of infection
  • Skin irritation


  1. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson’s disease in the United States. Movement Disord. 2013;28(3):311–318.
  2. Kalf JG, de Swart BJ, Borm GF, Bloem BR, Munneke M. Prevalence and definition of drooling in Parkinson’s disease: a systematic review. J Neurol. 2009;256(9):1391–1396.
  3. Centers for Disease Control and Prevention. Prevalence and most common causes of disability among adults – United States, 2005. MMWR Weekly. 2009;58(16):421–426. Updated April 30, 2009. Accessed November 19, 2020.
  4. Walshe M, Smith M, Pennington L. Interventions for drooling in children with cerebral palsy. Cochrane Database Syst Rev. 2012;11:CD008624.
  5. Tiigimäe-Saar J, Taba P, Tamme T. Does Botulinum neurotoxin type A treatment for sialorrhea change oral health? Clin Oral Invest. 2017;21(3):795–800.
  6. What is ALS? ALS Association website: Accessed November 19, 2020.
  7. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2020.
  8. Hockstein NG, Samadi DS, Gendron K, Handler SD. Sialorrhea: a management challenge. Am Fam Physician. 2004;69(11):2628–2634.